COMPANY PROFILE

Gencurix

Explore full profile

We're going one step ahead with excellent liquid biopsies

Seoul, South KoreaFounded 2011Biotech & Life Sciences

Valuation $100–250M Last recorded · 2021

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Gencurix

Gencurix specializes in molecular diagnostics, focusing on early cancer detection and personalized treatment strategies. The company operates in the healthcare sector, serving medical professionals and patients globally. Gencurix's core products include liquid biopsies and genetic tests, such as Geneswell BCT, which are designed to identify cancer at an early stage and tailor treatment plans to individual patients. The business model revolves around the development, production, and distribution of these diagnostic tools, generating revenue through sales to hospitals, clinics, and research institutions. Gencurix aims to improve patient outcomes and quality of life by providing accurate and timely diagnostic information.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2011
Headquarters: Seoul, South Korea
Employees: 32
Open positions: None listed
Dealroom signal: 83.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 2 companies, latest Jun 2026
Capital deployed: $1.3M
Preferred round: LATE VC
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Jun 2021	$23M	$91M	Korea Investment & Securities · Aju IB Investment · NH Investment & Securities	↗
SEEDOther financing	Oct 2018	$29M	$117M	Korea Investment Partners	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Gencurix website traffic

Latest recorded traffic for Gencurix is 2.8K monthly website visits, down 28.2% over the last three months. Gencurix's team grew 18.5% over the past year.

Latest monthly visits2.8K 3-month web change-28.2% 1-year team growth+18.5%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATALTx TherapeuticsFirst-in-class precision oncology targeting immortal cancer cell pathways.	Houghton and Wyton, United Kingdom	Operational	—	$13M	$50M
LPLX Bio PharmaceuticalsBiotechnology pharmaceutical company focused on developing antibody and bacteriophage therapies for unmet medical needs	Lisbon, Portugal	Operational
LSLife SI3D bioprinters and microfluidics systems for healthcare	Argentina	Operational
CHChemifyDigitizing chemistry by developing technology to convert chemical code into molecules and vice versa	Glasgow, United Kingdom	Operational
ETEnedra TherapeuticsDiscovering precision therapies targeting chromosomal instability to treat genetically heterogeneous cancers using computational genomics	Cambridge, United Kingdom	Operational
MTMETiS TherapeuticsAI-driven platform for drug discovery and delivery	Cambridge, United States	Operational
RBRarity BioscienceApplication: Rarity Safelock assay detects AML mutations	Uppsala kommun, Sweden	Operational
BIBioProNeoPharmaceutical and nutraceutical solutions for neonatal care	Breda, Netherlands	Operational